EGFR and colorectal carcinoma: As demonstrated in the context of both vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitors, gefitnib, and erlotinib were valid and valuable agents to overcome CRC (Normanno et al., 2010).